Nanotechnology - a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer.
Beilstein Journal Of Nanotechnology
Gorachinov, Filip F; Mraiche, Fatima F; Moustafa, Diala Alhaj DA; Hishari, Ola O; Ismail, Yomna Y; Joseph, Jensa J; Crcarevska, Maja Simonoska MS; Dodov, Marija Glavas MG; Geskovski, Nikola N; Goracinova, Katerina K
Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling.
Frontiers In Oncology
Hintzen, Gabriele G; Dulat, Holger J HJ; Rajkovic, Erich E
Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.
The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer.
Journal Of Clinical Medicine
Akhoundova, D D; Mosquera Martinez, J J; Musmann, L E LE; Britschgi, C C; Rütsche, C C; Rechsteiner, M M; Nadal, E E; Garcia Campelo, M R MR; Curioni-Fontecedro, A A
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).
Pharmaceuticals (Basel, Switzerland)
O'Leary, Connor C; Gasper, Harry H; Sahin, Katherine B KB; Tang, Ming M; Kulasinghe, Arutha A; Adams, Mark N MN; Richard, Derek J DJ; O'Byrne, Ken J KJ
Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.
Esmo Open
Berghoff, Anna S AS; Bellosillo, Beatriz B; Caux, Christophe C; de Langen, Adrianus A; Mazieres, Julien J; Normanno, Nicola N; Preusser, Matthias M; Provencio, Mariano M; Rojo, Federico F; Wolf, Jurgen J; Zielinski, Christoph C CC
Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report.
Oncotargets And Therapy
Zhang, Yan Y; He, Bixiu B; Zhou, Dongbo D; Li, Min M; Hu, Chengping C
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.
British Journal Of Cancer
Del Re, Marzia M; Bordi, Paola P; Rofi, Eleonora E; Restante, Giuliana G; Valleggi, Simona S; Minari, Roberta R; Crucitta, Stefania S; Arrigoni, Elena E; Chella, Antonio A; Morganti, Riccardo R; Tiseo, Marcello M; Petrini, Iacopo I; Danesi, Romano R
Third generation EGFR TKIs: current data and future directions.
Molecular Cancer
Tan, Chee-Seng CS; Kumarakulasinghe, Nesaretnam Barr NB; Huang, Yi-Qing YQ; Ang, Yvonne Li En YLE; Choo, Joan Rou-En JR; Goh, Boon-Cher BC; Soo, Ross A RA
Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
Annals Of Oncology : Official Journal Of The European Society For Medical Oncology
Yang, M M; Forbes, M E ME; Bitting, R L RL; O'Neill, S S SS; Chou, P-C PC; Topaloglu, U U; Miller, L D LD; Hawkins, G A GA; Grant, S C SC; DeYoung, B R BR; Petty, W J WJ; Chen, K K; Pasche, B C BC; Zhang, W W
Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Annals Of Oncology : Official Journal Of The European Society For Medical Oncology
Martinez-Marti, A A; Felip, E E; Matito, J J; Mereu, E E; Navarro, A A; Cedrés, S S; Pardo, N N; Martinez de Castro, A A; Remon, J J; Miquel, J M JM; Guillaumet-Adkins, A A; Nadal, E E; Rodriguez-Esteban, G G; Arqués, O O; Fasani, R R; Nuciforo, P P; Heyn, H H; Villanueva, A A; Palmer, H G HG; Vivancos, A A
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Lung Cancer (Auckland, N.Z.)
Santarpia, Mariacarmela M; Liguori, Alessia A; Karachaliou, Niki N; Gonzalez-Cao, Maria M; Daffinà, Maria Grazia MG; D'Aveni, Alessandro A; Marabello, Grazia G; Altavilla, Giuseppe G; Rosell, Rafael R